Algeta: New analyses from phase III ALSYMPCA trial in patients with castration-resistant prostate cancer to be presented at ESMO 2012

17 september 2012 Not intended for US media Safety of chemotherapy following Alpharadin treatment and Quality of Life analysis Oslo, Norway, 17 September 2012 - Algeta ASA (OSE: ALGETA) announces that further data and analysis from the phase III ALSYMPCA study of Alpharadin (radium-223 dichloride) in patients with metastatic castration-resistant prostate cancer will be presented at the ESMO 2012 Congress (Vienna, Austria; 28 September - 2 October 2012). Details of the presentations discussing Alpharadin, including a Special Symposium, are as follows: Abstract 936P Safety of cytotoxic chemotherapy following radium-223 chloride (Ra-223) therapy in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) with bone metastases Poster Presentation 1 Saturday, 29 September, 1:00pm-2:00pm, Hall XL Presented by Dr. Oliver Sartor, Medical Director Tulane Cancer Center, Tulane Medical School, and Principal Investigator for US arm of ALSYMPCA. Special Symposium: Re-inventing the medical treatment of advanced prostate cancer Sunday, 30 September, 9:00am-10:30am, Hall F1 Moderated by Professor Johann de Bono (Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK) and Dr. Oliver Sartor Abstract 898PD Updated survival, quality of life (QOL), and safety data of radium-223 chloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA) Poster Discussion, Genitourinary tumors, prostate Sunday, 30 September, 1:00pm-2:00pm, Hall C Presented by Dr. Christopher Parker (Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK), Principal Investigator for ALSYMPCA. Abstracts may be viewed at the ESMO 2012 Congress website: http://www.esmo.org/events/vienna-2012-congress.html ### For further information, please contact Mike Booth +47 2202 4510 Communications & Corporate Affairs ir@algeta.com International media enquiries: Mark Swallow +44 207 638 9571 Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk US investor enquiries: Tricia Swanson +1 646 378-2953 The Trout Group tswanson@troutgroup.com About Algeta Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Press release: http://hugin.info/134655/R/1641250/528507.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Algeta ASA via Thomson Reuters ONE [HUG#1641250]